- Companies
- Vaxxinity
Vaxxinity Valuation Multiples
Vaxxinity is valued at $13K. In the last fiscal year, Vaxxinity EBITDA was ($56M).
Vaxxinity Overview
About Vaxxinity
Vaxxinity Inc is a biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of synthetic, peptide-based active immunotherapy medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine, and hypercholesterolemia.
Founded
2021
HQ
Employees
65
Website
Financials (Last FY)
EV
$13K
Valuation Multiples
Start free trialVaxxinity Financials
Vaxxinity reported last fiscal year revenue of - and negative EBITDA of ($56M).
In the same fiscal year, Vaxxinity generated ($56M) in EBITDA losses and had net loss of ($57M).
Vaxxinity P&L
In the most recent fiscal year, Vaxxinity reported revenue of - and EBITDA of ($56M).
Vaxxinity is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Vaxxinity Stock Performance
Vaxxinity has current market cap of $13K, and enterprise value of $13K.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13K | $13K | - | - | - | - | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVaxxinity Valuation Multiples
Vaxxinity trades at (0.0x) EV/EBITDA.
Vaxxinity Financial Valuation Multiples
As of November 19, 2026, Vaxxinity has market cap of $13K and EV of $13K.
Vaxxinity has a P/E ratio of (0.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vaxxinity Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Vaxxinity Operational KPIs
Vaxxinity's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Vaxxinity Competitors
Vaxxinity competitors include Scorpius Holdings, Neovacs, Novaccess Global, M2Bio Sciences, Acutus Medical, Virpax Pharmaceuticals, Lipella Pharmaceuticals, Allurion, Lyra Therapeutics and Ocean Biomedical.
Most Vaxxinity public comparables operate across Biopharmaceuticals, Medical Devices and BioTech.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $6M | ($26M) | 1.9x | - | (0.5x) | - | |||
| $356K | ($6M) | 2.2x | - | (0.1x) | - | |||
| - | ($2M) | - | - | (0.0x) | - | |||
| $80M | $3M | 0.0x | - | 0.0x | - | |||
| $20M | $759K | 0.0x | - | 0.0x | - | |||
| - | ($12M) | - | - | (0.0x) | - | |||
| $536K | ($5M) | - | - | - | - | |||
| $15M | ($28M) | 1.6x | 1.7x | (0.9x) | - | |||
This data is available for Pro users. Sign up to see all Vaxxinity competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vaxxinity
| When was Vaxxinity founded? | Vaxxinity was founded in 2021. |
| Where is Vaxxinity headquartered? | Vaxxinity is headquartered in United States. |
| How many employees does Vaxxinity have? | As of today, Vaxxinity has over 65 employees. |
| Is Vaxxinity publicly listed? | Yes, Vaxxinity is a public company listed on OTCM. |
| What is the stock symbol of Vaxxinity? | Vaxxinity trades under VAXX ticker. |
| When did Vaxxinity go public? | Vaxxinity went public in 2021. |
| Who are competitors of Vaxxinity? | Vaxxinity main competitors include Scorpius Holdings, Neovacs, Novaccess Global, M2Bio Sciences, Acutus Medical, Virpax Pharmaceuticals, Lipella Pharmaceuticals, Allurion, Lyra Therapeutics, Ocean Biomedical. |
| What is the current market cap of Vaxxinity? | Vaxxinity's current market cap is $13K. |
| Is Vaxxinity profitable? | No, Vaxxinity is not profitable. |
| How many companies Vaxxinity has acquired to date? | Vaxxinity hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Vaxxinity has invested to date? | Vaxxinity hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Vaxxinity
Lists including Vaxxinity
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




